Hepatitis A: The costs and benefits of the disease prevention by vaccine, Paraná, Brazil

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 4, 2009, Pages 257-261

  Zahdi, Mariana Ribas ^a   Junior, Ivan Maluf ^a   Maluf, Eliane Mara Cesário Pereira ^a  

^a POSITIVO UNIVERSITY   (Brazil)

Author keywords

Cost benefit; Epidemiology; Hepatitis a; Vaccine

Indexed keywords

HEPATITIS A VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAZIL; CHILD; COST BENEFIT ANALYSIS; DATA BASE; DEATH; DRUG COST; FATIGUE; FEMALE; FEVER; HEALTH PROGRAM; HEPATITIS A; HOSPITAL COST; HUMAN; INCIDENCE; INFANT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LABORATORY TEST; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREVENTIVE HEALTH SERVICE; RASH; SEROCONVERSION; VACCINATION;

ADOLESCENT; ADULT; BRAZIL; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; VACCINATION; YOUNG ADULT;

EID: 77949812666     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702009000400003     Document Type: Article

References (28)

1. De Paula VS, Baptista ML, Lampe E, Niel C, Gaspar AM. Characterization of hepatitis A virus isolates from subgenotypes IA and IB in Rio de Janeiro, Brazil. J Med Virol 2002; 66: 22-27.
2. Valenzuela MTB. Vacunas anti hepatitis A: Estado del arte. Rev Chil Infect 1999; 16 (Supl. 1): 37-44.
3. th ed, 1998; 5-14.
4. th ed. Red Book 2003. Ed. Publicaç ões Científicas Ltda. p 355-363.
5. Almeida LM, Werneck GL, Cairncross S, Coeli CM, Costa MC, Coletty PE. The intensity of transmission of hepatitis A and heterogeneities in socio-environmental, risk factors in Rio de Janeiro, Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene 2002; 96: 605-610.
6. Guimaraens MA, Codeço CT. Experiments with mathematical models to simulate hepatitis A population dynamics under different levels of endemicity. Cad Saúde Pública 2005 Sep - Oct; 21 (5): 1531-9.
7. Lagos RZ, Potin M, Munoz A, Abrego P, San Martin OS, Ureta AM, et al. Anticuerpos séricos contra el virus hepatitis A en sujetos de nivel socioeconómico medio y bajo, en comunas urbanas de Santiago. Rev Méd Chile 1999; 127: 429-436.
8. Sonder GJB, Van Steenbergen JE, Bovee LP, Peerbooms PG, Coutinho RA, Van DEN Hoek A. Hepatitis A virus immunity and seroconversion among contacts of acute hepatitis A patients in Amsterdam, 1996-2000: An evaluation of current prevention policy. Am J Public Health 2004; 94: 1620-1626.
9. Proll S, Nothdurft HD. The risks of contracting hepatitis A or hepatitis B run by visitors to the Mediterranean and Eastern Europe. MMW Fortschr Med 2004; 146 (20): 51-54.
10. Medronho RA, Ribeiro SV, Valencia LIO, Fortes BPMD, Braga RCC. Análise espacial da soroprevalência da hepatite A em crianças de uma região carente de Duque de Caxias, RJ, Brasil. Rev Bras Epidemiol 2003; 6:328-34.
11. Gendrel D. Hepatitis A vaccination in children. Med Trop (Mars) 2004; 64 (4): 394-400.
12. Andre F, Van Damme P, Safary A, Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines 2002; 1 (1), 9-23.
13. Soogarun S, Wiwanitkit V. Vaccinating Thai adolescents against hepatitis A: is it cost- effective? Southeast Asian J Trop Med Public Health, 2002; 33 Suppl 3:145-8.
14. Yang CY, Lu CY, Lee CY, Shao PL, Wang CY, Wu TZ, et al. An open study of inactivated hepatitis A vaccine (VAQTA) in Taiwanese healthy adult volunteers: safety, tolerability, and immunogenicity. Microbiol Immunol Infect 2004; 37 (4): 216-218.
15. Ferreira CT, Pereira Lima J, Barros FC. Soroepidemiologia da hepatite A em dois grupos populacionais economicamente distintos de Porto Alegre. GED 1996; 15 (3): 85-90.
16. Focaccia R, da Conceição OJ, Sette H Jr, Sabino E, Bassit L, Nitrini DR, et al. Estimated prevalence of viral hepatitis in the general population of the municipality of Sao Paulo, measured by a serologic survey of a stratified, randomized and residencebased population. Braz J Infect Dis 1998 Dec; 2 (6): 269-284.
17. Department of Health and Human Services. CDC - Centers for Disease Control and Prevention. Disponível em: http:// www.cdc.gov/ Accessed: 12/15/2005.
18. MMWR Morb Mortal Wkly Rep. 1999;vol.48:247-252.
19. a edição ampliada, 2004, págs. 168-172.
20. Ciocca et al. Clinical course and consequences of hepatitis A infection. Vaccine. Vol. 18, Sup. 1, Feb. 2000, P S71-S74
21. Debbag et al. 10 Years Experience in Fulminant Hepatic Failure due to Hepatitis A. Costs and Evolution. ICID 2004 Abstract No. 1682.
22. Lopez, E.; Debbag, R. ; Coudeville, F. ; Papillon, J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health - economic analysis. Journal of Gastroenterology. Vol. 42, N. 2 / Feb., 2007.
23. Valenzuela MT, Jacobs RJ, Arteaga O, Navarrete MS, Meyerhoff AS, Innis BL. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 2005 Jul; 23 (32): 4110-9.
24. Jacobs RJ, Greenberg DP, Koff RS, Saab S, Meyerhoff AS. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J., 2003 Oct; 22(10): 904-14.
25. Deneke MG, Arguedas MR. Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs. Expert Rev Vaccines 2003 Oct; 2 (5): 661-72.
26. Dagan R, Leventhal A, Anis E, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA, 294:202-210; 2005.
27. Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults. Hepatology, 2003 Jan; 37 (1): 44-51.
28. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA, 294:194-201; 2005.